The proof-of-concept study for TRV734 resumes following NIDA ‘s recruitment of patients. In addition, Trevena Inc (NASDAQ: TRVN) announces its move today, pointing to the move towards the right direction in activities centered on developing and commercializing novel medicines to support struggling patients. The company has, over the years, sought out […]